Louise Chen

“I just wanted to ask you on payer coverage. When do you expect that to ramp up and, you know, what are the different stages here? What is the out-of-pocket cost per patient?”

“I wanted to ask you about some of your other pipeline products outside of obesity. I know you've put a lot in there. Any specific assets, one or two, that you're really excited about that you think the street should be paying more attention to?”

“I wanted to ask you on SkyRizzy subcutaneous, if you get this approved in the fall, do you expect that to drive an acceleration of sales in the second half of the year for SkyRizzy?”

“I wanted to ask you about your biosimilars opportunity. You seem to be talking about that more. And just curious if you could give us a little bit more color on why the growth opportunity is becoming more meaningful now to you.”

“I wanted to ask you about the Caden study. There was some debate on the results that you recently presented at a medical meeting, and I'm wondering what you think the street may be missing about the competitiveness of your product.”